Voyager to Present at Oppenheimer 25th Annual Healthcare Life Sciences Conference
Voyager Therapeutics (Nasdaq: VYGR), a biotechnology company focused on neurogenetic medicines, has announced its participation in the Oppenheimer 25th Annual Healthcare Life Sciences Conference. The company will engage in a fireside chat scheduled for February 11, 2025, at 2:40 p.m. ET.
The presentation will be accessible via webcast through the Investors section of Voyager's website at ir.voyagertherapeutics.com. Interested parties can access a replay of the webcast, which will remain available on the company's website for a minimum of 30 days following the presentation.
Voyager Therapeutics (Nasdaq: VYGR), un'azienda biotecnologica focalizzata su medicinali neurogenetici, ha annunciato la sua partecipazione alla 25ª Conferenza Annuale Oppenheimer sulle Scienze della Vita e Sanità. L'azienda parteciperà a una chiacchierata informale programmata per 11 febbraio 2025, alle 14:40 ET.
La presentazione sarà accessibile tramite webcast nella sezione Investitori del sito di Voyager all'indirizzo ir.voyagertherapeutics.com. Le parti interessate possono accedere a una registrazione del webcast, che rimarrà disponibile sul sito dell'azienda per un minimo di 30 giorni dopo la presentazione.
Voyager Therapeutics (Nasdaq: VYGR), una empresa biotecnológica centrada en medicamentos neurogenéticos, ha anunciado su participación en la 25ª Conferencia Anual Oppenheimer sobre Ciencias de la Vida y Atención Sanitaria. La empresa participará en una charla informal programada para 11 de febrero de 2025, a las 2:40 p.m. ET.
La presentación estará disponible a través de un webcast en la sección de Inversores del sitio web de Voyager en ir.voyagertherapeutics.com. Las partes interesadas podrán acceder a una repetición del webcast, que estará disponible en el sitio web de la empresa durante un mínimo de 30 días tras la presentación.
보이저 테라퓨틱스 (Nasdaq: VYGR), 신경 유전 의약품에 초점을 맞춘 생명공학 회사가 오펜하이머 제25회 연례 건강 및 생명 과학 컨퍼런스에 참여한다고 발표했습니다. 회사는 2025년 2월 11일 오후 2시 40분 ET에 예정된 화상 대화에 참여할 예정입니다.
발표는 보이저 웹사이트의 투자자 섹션(ir.voyagertherapeutics.com)을 통해 웹캐스트를 통해 접근할 수 있습니다. 관심 있는 당사자는 발표 후 최소 30일 동안 회사 웹사이트에서 제공되는 웹캐스트 다시 보기를 이용할 수 있습니다.
Voyager Therapeutics (Nasdaq: VYGR), une entreprise biotechnologique axée sur les médicaments neurogénétiques, a annoncé sa participation à la 25ème Conférence Annuelle Oppenheimer sur les Sciences de la Vie et la Santé. L'entreprise prendra part à une discussion informelle prévue pour le 11 février 2025 à 14h40 ET.
La présentation sera accessible via un webcast dans la section Investisseurs du site de Voyager à l'adresse ir.voyagertherapeutics.com. Les parties intéressées peuvent accéder à un enregistrement du webcast, qui restera disponible sur le site de l'entreprise pendant au moins 30 jours après la présentation.
Voyager Therapeutics (Nasdaq: VYGR), ein Biotechnologieunternehmen, das sich auf neurogenetische Medikamente spezialisiert hat, hat seine Teilnahme an der 25. jährlichen Oppenheimer Healthcare Life Sciences Konferenz bekannt gegeben. Das Unternehmen wird an einem geplanten Fireside-Chat am 11. Februar 2025 um 14:40 Uhr ET teilnehmen.
Die Präsentation wird über einen Webcast auf der Investorenseite der Voyager-Website unter ir.voyagertherapeutics.com zugänglich sein. Interessierte Parteien können eine Wiederholung des Webcasts abrufen, der mindestens 30 Tage nach der Präsentation auf der Website des Unternehmens verfügbar bleibt.
- None.
- None.
LEXINGTON, Mass., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it will participate in a fireside chat at the Oppenheimer 25th Annual Healthcare Life Sciences Conference at 2:40 p.m. ET on February 11, 2025.
A webcast of the presentation will be available and may be accessed from the Investors section of Voyager’s website at ir.voyagertherapeutics.com. A replay of the webcast will be archived on the Company’s website for at least 30 days.
About Voyager Therapeutics
Voyager Therapeutics, Inc. (Nasdaq: VYGR) is a biotechnology company dedicated to leveraging the power of human genetics to modify the course of – and ultimately cure – neurological diseases. Our pipeline includes programs for Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple other diseases of the central nervous system. Many of our programs are derived from our TRACER™ AAV capsid discovery platform, which we have used to generate novel capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Some of our programs are wholly owned, and some are advancing with partners including Alexion, AstraZeneca Rare Disease; Novartis Pharma AG; and Neurocrine Biosciences, Inc. For more information, visit www.voyagertherapeutics.com.
Voyager Therapeutics® is a registered trademark, and TRACER™ is a trademark, of Voyager Therapeutics, Inc.
Contacts
Trista Morrison, NACD.DC, tmorrison@vygr.com
Investors: Mike Hencke, mhencke@kendallir.com
Media: Brooke Shenkin, brooke@scientpr.com
FAQ
When is Voyager Therapeutics (VYGR) presenting at the Oppenheimer Healthcare Conference 2025?
How can investors access Voyager Therapeutics' (VYGR) Oppenheimer Conference presentation?
How long will the replay of VYGR's Oppenheimer Conference presentation be available?
What type of presentation will VYGR deliver at the 2025 Oppenheimer Healthcare Conference?
